Zymeworks Inc. (ZYME)

NMS – Real Time Price. Currency in USD

24.15

+0.38 (1.60%)

At close: Jun 26, 2026, 4:00 PM EDT

24.15

-0.00 (-0.00%)

After-hours: Jun 26, 2026, 4:31 PM EDT

14.06.2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.

22.05.2026

Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality

Zymeworks is transitioning into an oncology royalty platform with a robust internal discovery engine, offering a differentiated risk-reward profile versus traditional biotech peers. ZYME's balance sheet is fortified with over $400 million in liquid assets, a $440 million milestone pipeline, and a $125 million share repurchase program, supporting operations beyond 2028. Zanidatamab's Priority Review for first-line HER2-positive GEA, with a PDUFA date of August 25, 2026, could trigger $265 million in near-term milestone payments and unlock substantial royalty streams.

14.05.2026

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a 2026 share repurchase program under which the Company may repurchase up to $125.0 million of its outstanding common stock, par value $0.00001 per share. Concurrently, Zymeworks has terminated its existing 2025 share repurchase program under which the Company has repurchased 4,197,553 million shares of common stock for $102.3 million, representing an average purchase price of $24.36 per common share.

13.05.2026

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:

09.05.2026

Zymeworks Q1 Earnings Call Highlights

Zymeworks NASDAQ: ZYME reported a wider first-quarter loss as revenue declined from year-earlier milestone payments, while management highlighted regulatory catalysts for zanidatamab, progress across its antibody-drug conjugate pipeline and continued share repurchases.

09.05.2026

Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript

08.05.2026

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.3 per share a year ago.

Videos

No Data

There is no data to display

Press releases

14.06.2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

14.05.2026

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

07.05.2026

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026 China's NMPA has accepted the sBLA for zanidatamab; the U.S. FDA has granted Breakthrough Therapy Designation to zanidatamab in combination with fluoropyrimidine- and platinum-based chemotherapy (±) TEVIMBRA, for this indication. Presented new data from our Phase 1 trial of ZW191 at AACR, continuing to support best-in-class potential in ovarian and endometrial cancers Presented on emerging RAS inhibitor antibody-drug conjugate platform at AACR $95.8 million utilized for share repurchases as of May 6, 2026 under the current authorized share repurchase program Reported $403.8 million in cash, cash equivalents and marketable securities as of March 31, 2026 Conference call with management today at 4:30 p.m.

21.04.2026

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced results from the dose-escalation part of the Phase 1 study for ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

Zymeworks Inc. (ZYME)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Zymeworks Inc. (ZYME)

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Q1 Earnings Call Highlights

Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

Videos

No Data

Press releases

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Q1 Earnings Call Highlights

Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

Videos

No Data

Press releases

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Search stocks

Zymeworks Inc. (ZYME)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Zymeworks Inc. (ZYME)

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Q1 Earnings Call Highlights

Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

Videos

No Data

Press releases

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Q1 Earnings Call Highlights

Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

Videos

No Data

Press releases

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026